[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20056020L - Smapartiklet farmasoytisk formulering av midler mot anfall og demens, og immunsuppresjonsmidler - Google Patents

Smapartiklet farmasoytisk formulering av midler mot anfall og demens, og immunsuppresjonsmidler

Info

Publication number
NO20056020L
NO20056020L NO20056020A NO20056020A NO20056020L NO 20056020 L NO20056020 L NO 20056020L NO 20056020 A NO20056020 A NO 20056020A NO 20056020 A NO20056020 A NO 20056020A NO 20056020 L NO20056020 L NO 20056020L
Authority
NO
Norway
Prior art keywords
immunosuppressants
smaparticle
antidepressant
pharmaceutical formulation
dementia agents
Prior art date
Application number
NO20056020A
Other languages
English (en)
Inventor
Mark J Doty
Christine L Rebbeck
Jane Werling
Rabinow E Barrett
Jamie Teresa Konkel
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Publication of NO20056020L publication Critical patent/NO20056020L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formulering med småpartiklede suspensjoner av antikonvulsanter, særlig karbamazepin, for farmasøytisk anvendelse. Oppfinnelsen angår også en formulering med småpartiklede suspensjoner av immunsuppresjonsmidler, særlig syklosporin, for farmasøytisk anvendelse. Partiklene er overtrukket med ett eller flere overflatemodifiserende midler.
NO20056020A 2003-05-19 2005-12-16 Smapartiklet farmasoytisk formulering av midler mot anfall og demens, og immunsuppresjonsmidler NO20056020L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47158103P 2003-05-19 2003-05-19
PCT/US2004/015621 WO2004103348A2 (en) 2003-05-19 2004-05-19 Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers

Publications (1)

Publication Number Publication Date
NO20056020L true NO20056020L (no) 2005-12-16

Family

ID=33476859

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20056020A NO20056020L (no) 2003-05-19 2005-12-16 Smapartiklet farmasoytisk formulering av midler mot anfall og demens, og immunsuppresjonsmidler

Country Status (11)

Country Link
US (1) US20050244503A1 (no)
EP (1) EP1628641A2 (no)
JP (1) JP2006528985A (no)
KR (1) KR20060012628A (no)
CN (1) CN1791386A (no)
AU (1) AU2004240640A1 (no)
BR (1) BRPI0410767A (no)
CA (1) CA2524538A1 (no)
MX (1) MXPA05012467A (no)
NO (1) NO20056020L (no)
WO (1) WO2004103348A2 (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69633222T2 (de) * 1995-02-24 2005-09-08 Elan Pharma International Ltd. Nanopartikel-dispersionen enthaltende aerosole
EP2266542A3 (en) * 1998-10-01 2013-07-31 Elan Pharma International Limited Controlled release nanoparticulate compositions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
CA2461349C (en) 2001-09-26 2011-11-29 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
CA2475092C (en) 2002-02-04 2012-05-01 Christian F. Wertz Nanoparticulate compositions having lysozyme as a surface stabilizer
EP1587499A1 (en) * 2003-01-31 2005-10-26 Elan Pharma International Limited Nanoparticulate topiramate formulations
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
CA2540695A1 (en) * 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
US8986736B2 (en) * 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
US7824697B2 (en) 2004-07-12 2010-11-02 Board Of Regents, The University Of Texas System High concentration baclofen preparations
AU2005316473B2 (en) * 2004-12-15 2011-07-14 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
WO2006101972A2 (en) * 2005-03-17 2006-09-28 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
MX2007012762A (es) * 2005-04-12 2008-01-14 Elan Pharma Int Ltd Composiciones de material nanoparticulado y de liberacion controlada que comprende ciclosporina.
EA014611B1 (ru) * 2005-04-12 2010-12-30 Элан Фарма Интернэшнл Лтд. Готовые формы из наночастиц производных хиназолина
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
BRPI0600285C1 (pt) * 2006-01-13 2011-10-11 Brz Biotecnologia Ltda compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
CN101848704A (zh) * 2007-07-24 2010-09-29 耐百生物制药有限公司 用于制备微粒的技术
RU2496482C2 (ru) * 2008-03-05 2013-10-27 Бакстер Интернэшнл Инк. Композиции и способы для доставки лекарственных средств
US8969414B2 (en) 2009-02-06 2015-03-03 Mallinckrodt Llc Intrathecal baclofen pharmaceutical dosage forms with fewer degradation products
US20150258279A1 (en) 2008-03-18 2015-09-17 Mallinckrodt Llc Intrathecal baclofen pharmaceutical dosage forms and related delivery system
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
WO2011069629A2 (en) 2009-12-10 2011-06-16 Merck Patent Gmbh Pharmaceutical composition comprising oligopeptides
WO2012039979A2 (en) * 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
EP2717854B1 (en) 2011-06-09 2019-01-16 Merck Patent GmbH Treatment of cancers and metastases with suspensions of cilengitide in carrier
US20140178479A1 (en) * 2011-08-12 2014-06-26 Perosphere, Inc. Concentrated Felbamate Formulations for Parenteral Administration
JP2015527310A (ja) 2012-06-28 2015-09-17 アンサン バイオファーマ, インコーポレイテッドAnsun Biopharma, Inc. 下気道および中枢気道への送達用微粒子製剤ならびに製造方法
BR112015012547A2 (pt) * 2012-11-30 2017-07-11 Insmed Inc composições de prostaciclina e métodos de sua utilização
US9469600B2 (en) 2013-10-25 2016-10-18 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
AU2015349969B2 (en) 2014-11-18 2020-02-06 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
WO2017066626A1 (en) * 2015-10-16 2017-04-20 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
US20180296487A1 (en) * 2017-04-18 2018-10-18 Marinus Pharmaceuticals, Inc. Sustained release injectable neurosteroid formulations
WO2019186515A1 (en) * 2018-03-30 2019-10-03 Ftf Pharma Private Limited Liquid pharmaceutical compositions of antiepileptic drugs
CA3138530A1 (en) 2019-04-29 2020-11-05 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2948718A (en) * 1960-08-09 New n-heterocyclic compounds
US4608278A (en) * 1983-06-22 1986-08-26 The Ohio State University Research Foundation Small particule formation and encapsulation
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
CA1338736C (fr) * 1986-12-05 1996-11-26 Roger Baurain Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
GB9024366D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5720551A (en) * 1994-10-28 1998-02-24 Shechter; Tal Forming emulsions
SE9403846D0 (sv) * 1994-11-09 1994-11-09 Univ Ohio State Res Found Small particle formation
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5716642A (en) * 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
ES2208946T3 (es) * 1996-08-23 2004-06-16 Sequus Pharmaceuticals, Inc. Liposomas que contienen un compuesto de cisplatino.
EP0954282B1 (en) * 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Preparation of particles for inhalation
IL162023A0 (en) * 1998-03-30 2005-11-20 Rtp Pharma Inc Compositions containing microparticles of water-insoluble substances and method for their preparation
ATE228823T1 (de) * 1998-04-18 2002-12-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
DK1169019T3 (da) * 1999-04-14 2003-06-02 Glaxo Group Ltd Farmaceutisk aerosolformulering
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems

Also Published As

Publication number Publication date
EP1628641A2 (en) 2006-03-01
MXPA05012467A (es) 2006-02-22
CA2524538A1 (en) 2004-12-02
BRPI0410767A (pt) 2006-07-04
US20050244503A1 (en) 2005-11-03
JP2006528985A (ja) 2006-12-28
CN1791386A (zh) 2006-06-21
WO2004103348A3 (en) 2005-01-06
KR20060012628A (ko) 2006-02-08
WO2004103348A2 (en) 2004-12-02
AU2004240640A1 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
NO20056020L (no) Smapartiklet farmasoytisk formulering av midler mot anfall og demens, og immunsuppresjonsmidler
DE602006017579D1 (de) Klebstoff für optischen film sowie von dem klebstoff gebrauch machendes klebevlies und optisches glied
LTPA2018502I1 (lt) Per burną vartojamos kladribino kompozicijos
AU305551S (en) Bottle
AU305158S (en) Bottle
GB0526397D0 (en) Facilitating the sale of ad items via the internet
DE60326611D1 (de) N und dergleichen
DK1725540T5 (da) Diaminopyrimidiner som p2x3- og p2x2/3-antagonister
ATE381893T1 (de) Aromapartikel
DE602005027546D1 (de) Aryl- und heteroarylpiperidincarboxylatderivate, deren herstellung und deren verwendung in form von faah-enzyminhibitoren
AU305552S (en) Bottle
NO20051281D0 (no) Sammensetning for anrikning av naeringsmidler
IL186102A0 (en) Alpha ketoamide derivatives and pharmaceutical compositions containing the same
DK1667668T3 (da) Alfabeta3 og altabeta6-integrinantagonister som antifibrotiske midler
ITRM20050103A1 (it) Associazione di antagonisti della interleuchina 6 e farmaci antiproliferativi.
DE602004015741D1 (de) Parfumteilchen und das Verfahren zu deren Herstellung
ITFI20020038A1 (it) Coloranti ceramici in forma di sospensioni nanometriche
ATE478045T1 (de) Derivate von 4,5-diarylpyrrol, verfahren zu deren herstellung und deren verwendung in therapeutika
NO20054535L (no) Bifunksjonelle heterocykliske forbindelser og fremgangsmater for fremstilling og anvendelse av samme
ATE487706T1 (de) Cyclische n-ä1,3,4ü-thiadiazol-2-yl- benzsulfonamide, verfahren zu deren herstellung und deren verwendung als arzneimittel
FR2846327B1 (fr) Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant.
DE60332076D1 (de) Doppelmessverfahren zur Anzeige des Inhalts von Poststücken
ITMI20022358A1 (it) Composizioni farmaceutiche effervescenti per la realizzazione di sospensioni non convenzionali.
ATE395937T1 (de) Zur erhöhung der konzentration von radioaktivem biotin bei der pretargeted radioimmuntherapie wirksame avidindimere
ITBO20020667A1 (it) Macchina per la lavorazione di pannelli di legno o simili.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application